-
公开(公告)号：US20170088620A1
公开(公告)日：2017-03-30
申请号：US15279162
申请日：2016-09-28
申请人： Amgen Inc.
发明人： Paul Nioi , Peter Coward , Christopher Murawsky , Derek E. Piper , Fernando Garces , Jun Zhang , Yang Li , Brian Mintung Chang
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
CPC分类号： C07K16/2851 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61P9/04 , A61P9/10 , C07H21/02 , C07K14/705 , C07K16/28 , C07K2317/30 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N15/1138
摘要： Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
-
公开(公告)号：US12012462B2
公开(公告)日：2024-06-18
申请号：US17046731
申请日：2019-04-10
申请人： AMGEN INC. , KiTe Pharma, Inc.
发明人： Michael John Giffin , Melissa Thomas , Christopher Murawsky , Ryan B. Case , Lawren Wu , Jed J. Wiltzius , Ruben Alvarez Rodriguez , Jun Feng
IPC分类号： C07K16/30 , A61K39/00 , A61P35/00 , C07K14/705 , C12N15/86
CPC分类号： C07K16/30 , A61P35/00 , C07K14/70517 , C07K14/70521 , C12N15/86 , A61K2039/505 , C07K2317/565 , C07K2317/622 , C12N2740/15041
摘要： Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.
-
3.发明授权公开(公告)号：US11066472B2
公开(公告)日：2021-07-20
申请号：US16230356
申请日：2018-12-21
申请人： Amgen Inc.
发明人： Paul Nioi , Peter Coward , Christopher Murawsky
IPC分类号： A61P9/10 , A61P3/06 , A61K39/395 , C07K16/28 , A61P9/04 , C12N15/113 , C07H21/02 , A61K45/06 , C07K14/705 , A61K39/00
摘要： Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
-
4.发明授权公开(公告)号：US12060430B2
公开(公告)日：2024-08-13
申请号：US17332578
申请日：2021-05-27
申请人： AMGEN INC.
发明人： Junming Yie , Donghui Shi , David J. Lloyd , Jinghong Wang , Glenn N. Sivits, Jr. , Murielle M. Veniant-Ellison , Renee Komorowski , Neeraj Agrawal , Darren L. Bates , Brandon C. P. Clavette , Ian N. Foltz , Shu-yin Ho , Christopher Murawsky , Xiaoshan Min , Zhulun Wang
CPC分类号： C07K16/2869 , A61K9/0019 , A61K38/1703 , A61K38/26 , A61K39/3955 , A61K2039/505 , A61K2039/54 , C07K2299/00 , C07K2317/21 , C07K2317/32 , C07K2317/33 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2317/76 , C07K2317/92 , A61K39/3955 , A61K2300/00
摘要： Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
公开(公告)号：US20210163601A1
公开(公告)日：2021-06-03
申请号：US16987237
申请日：2020-08-06
申请人： Amgen Inc.
发明人： Paul Nioi , Peter Coward , Christopher Murawsky , Derek E. Piper , Fernando Garces , Jun Zhang , Yang Li , Brian Mingtung Chan
IPC分类号： C07K16/28 , A61P9/10 , A61P9/04 , C12N15/113 , C07H21/02 , A61P3/06 , A61K39/395 , A61K45/06
摘要： Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
-
公开(公告)号：US20190248902A1
公开(公告)日：2019-08-15
申请号：US16230356
申请日：2018-12-21
申请人： Amgen Inc.
发明人： Paul Nioi , Peter Coward , Christopher Murawsky , Derek E. Piper , Fernando Garces , Jun Zhang , Yang Li , Brian Mingtung Chan
IPC分类号： C07K16/28 , C07H21/02 , A61K39/395 , A61P9/10 , A61P9/04 , A61K45/06 , C12N15/113
CPC分类号： C07K16/2851 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61P9/04 , A61P9/10 , C07H21/02 , C07K14/705 , C07K16/28 , C07K2317/30 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N15/1138
摘要： Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
-
公开(公告)号：US11046774B2
公开(公告)日：2021-06-29
申请号：US16285118
申请日：2019-02-25
申请人： AMGEN INC.
发明人： Junming Yie , Donghui Shi , David J. Lloyd , Jinghong Wang , Glenn N. Sivits, Jr. , Murielle M. Veniant-Ellison , Renee Komorowski , Neeraj Agrawal , Darren L. Bates , Brandon C. P. Clavette , Ian N. Foltz , Shu-yin Ho , Christopher Murawsky , Xiaoshan Min , Zhulun Wang
摘要： Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
公开(公告)号：US20190276546A1
公开(公告)日：2019-09-12
申请号：US16285118
申请日：2019-02-25
申请人： AMGEN INC.
发明人： Junming Yie , Donghui Shi , David J. Lloyd , Jinghong Wang , Glenn N. Sivits, JR. , Murielle M. Veniant-Ellison , Renee Komorowski , Neeraj Agrawal , Darren L. Bates , Brandon C. P. Clavette , Ian N. Foltz , Shu-yin Ho , Christopher Murawsky , Xiaoshan Min , Zhulun Wang
IPC分类号： C07K16/28 , A61K9/00 , A61K38/26 , A61K39/395 , A61K38/17
摘要： Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
公开(公告)号：US10294303B2
公开(公告)日：2019-05-21
申请号：US15387542
申请日：2016-12-21
申请人： AMGEN INC.
发明人： Junming Yie , Donghui Shi , David J. Lloyd , Jinghong Wang , Glenn N. Sivits, Jr. , Murielle M. Veniant-Ellison , Renee Komorowski , Neeraj Agrawal , Darren L. Bates , Brandon C. P. Clavette , Ian N. Foltz , Shu-yin Ho , Christopher Murawsky , Xiaoshan Min , Zhulun Wang
摘要： Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.064 秒)
